Pharvaris (PHVS) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

The mean of analysts' price targets for Pharvaris (PHVS) points to a 79.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnin…

ZUG, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living w…

ZUG, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living w…

Pivotal, Phase 3 CHAPTER-3 data selected for late-breaking oral presentation on Saturday, November 14 Pivotal, Phase 3 CHAPTER-3 data selected for late-breaking oral presentation on Saturday, November 14…

Bank of America Securities on Friday upgraded Pharvaris N.V. (NASDAQ:PHVS), citing an attractive entry point with clinical risk largely removed.…

ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bra…

Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) Director Robert Glassman sold 14,493 shares of Pharvaris stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $38.56, for a to…

Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) insider Anne Lesage sold 20,000 shares of the company's stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $38.27, for a total …

Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) insider Anne Lesage sold 30,000 shares of the company's stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $38.30, for a total…

Squarepoint Ops LLC lowered its stake in Pharvaris N.V. (NASDAQ: PHVS) by 53.7% during a recent quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 44,629 shares of the co…

Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.…

Pharvaris N.V. maintains a 'Strong Buy' rating following pivotal phase 3 wins for both on-demand and prophylactic HAE therapies. PHVS achieved rapid symptom relief in RAPIDe-3 [median 1.28 hours, p…

Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema Transcript…

Pharvaris said on Tuesday its experimental oral drug helped prevent swelling attacks in patients with hereditary angioedema, meeting the main goal of a late-stage trial.…

ZUG, Switzerland, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living …

ZUG, Switzerland, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with br…

BlackRock Inc. purchased a new stake in shares of Pharvaris N.V. (NASDAQ: PHVS) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 771,454 share…

5AM Venture Management LLC bought a new stake in shares of Pharvaris N.V. (NASDAQ: PHVS) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 797,600…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

